InVivo, CEVEC pharmaceuticals Sign License Agreement

CEVEC Pharmaceuticals and InVivo BioTech Services have signed a strategic license agreement. The license enables InVivo to use the proprietary CAP-T transient expression system.

CAP-T Technology is based on CAP cells, the stable cell line from CEVEC.

Wolfgang Kintzel, CCO of CEVEC Pharmaceuticals, said: “After launching our new transient cell in the US market we are delighted to have now our first customers in Europe not only using our stable expression system but also working with our new transiently expressing human cell line. With expression rates outperforming any other human system on the market, eg HEK 293 freestyle and others, while offering highest quality human like proteins, we offer our customers a unique state of the art cell line.”

Rainer Lichtenberger, CEO of CEVEC, said: “Because posttranslational modifications play a significant role for the bioactivity of recombinant proteins it is of crucial importance to produce proteins with human-like glycosylation and sialylation. With our proprietary human cell lines, CAP for permanent producer cells for proteins and the novel CAP-T system, only CEVEC is able to offer a unique range of versatile human cell expression systems to our customers, from early discovery to protein manufacture. This license agreement contributes significantly to CEVECs goal becoming the leading cell line supplier for protein production with human cell expression systems.”